Role of microRNAs in T Cell-Driven Inflammation in Asthma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 5/6/2018 |
| Start Date: | October 2011 |
| End Date: | December 2018 |
Role of miRNAs in Th2-driven Inflammation in Asthma
This will be a single center study of asthmatic subjects and healthy controls which will
investigate mechanisms of asthma through detailed molecular analysis of airway tissues and
fluids. The primary goal will be investigate the role of microRNAs in Th2-driven inflammation
in asthma. The investigators hypothesize that asthma is associated with abnormal expression
of miRNAs in T cells which favors differentiation into Th2-cells. The investigators further
hypothesize that asthma is heterogeneous based on the presence and absence of Th2-driven
inflammation and that abnormalities in T cell miRNA expression will be most prominent in a
subgroup with high levels of Th2-driven inflammation (as assessed using molecular markers
that the investigators have previously established). Finally, the investigators hypothesize
that inhaled corticosteroids will normalize the T-cell miRNA abnormalities observed in
asthma, as corticosteroids treat Th2-driven inflammation. The samples collected will also
facilitate the pursuit of secondary analyses designed to investigate mechanisms of
inflammation and remodeling in asthma as well as molecular phenotypes of asthma.
investigate mechanisms of asthma through detailed molecular analysis of airway tissues and
fluids. The primary goal will be investigate the role of microRNAs in Th2-driven inflammation
in asthma. The investigators hypothesize that asthma is associated with abnormal expression
of miRNAs in T cells which favors differentiation into Th2-cells. The investigators further
hypothesize that asthma is heterogeneous based on the presence and absence of Th2-driven
inflammation and that abnormalities in T cell miRNA expression will be most prominent in a
subgroup with high levels of Th2-driven inflammation (as assessed using molecular markers
that the investigators have previously established). Finally, the investigators hypothesize
that inhaled corticosteroids will normalize the T-cell miRNA abnormalities observed in
asthma, as corticosteroids treat Th2-driven inflammation. The samples collected will also
facilitate the pursuit of secondary analyses designed to investigate mechanisms of
inflammation and remodeling in asthma as well as molecular phenotypes of asthma.
Group A:
Inclusion Criteria:
- Male and female subjects between the ages of 18 and 70 years
Group B:
Inclusion Criteria:
- Male and female subjects between the ages of 18 and 70 years
- History of asthma
- No use of oral or inhaled corticosteroids for the treatment of asthma in the past 6
weeks
- Hyperreactivity to methacholine (PC20FEV1 Methacholine ≤ 8.0 mg/mL)
- At least one of the following symptoms, beta agonist use, or FEV1 criteria:
- Asthma symptoms on at least two days per week; OR
- Beta agonist use on at least two days per week; OR
- FEV1 < 85% predicted
Groups A & B:
Exclusion Criteria:
- Current smokers (smoking within the last 12 months) or former smokers who have a total
pack-year smoking history greater than 10
- Pregnant women
- Subjects with a history of lung disease other than asthma
- Subjects with a history of a medical disease, which in the opinion of the investigator
may put the subject at extra risk from study-related procedures or because the disease
may influence the results of the study
We found this trial at
1
site
Click here to add this to my saved trials
